BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35900763)

  • 1. Assessment of Second Primary Cancer Risk Among Men Receiving Primary Radiotherapy vs Surgery for the Treatment of Prostate Cancer.
    Bagshaw HP; Arnow KD; Trickey AW; Leppert JT; Wren SM; Morris AM
    JAMA Netw Open; 2022 Jul; 5(7):e2223025. PubMed ID: 35900763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer.
    Rasmussen KM; Patil V; Li C; Yong C; Appukkuttan S; Grossman JP; Jhaveri J; Halwani AS
    JAMA Netw Open; 2023 Oct; 6(10):e2337272. PubMed ID: 37819658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
    Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
    JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015.
    Pithadia KJ; Advani PG; Citrin DE; Bekelman JE; Withrow DR; Berrington de Gonzalez A; Morton LM; Schonfeld SJ
    JAMA Oncol; 2023 Aug; 9(8):1119-1123. PubMed ID: 37289449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018.
    Parikh RB; Robinson KW; Chhatre S; Medvedeva E; Cashy JP; Veera S; Bauml JM; Fojo T; Navathe AS; Malkowicz SB; Mamtani R; Jayadevappa R
    JAMA Netw Open; 2020 Sep; 3(9):e2018318. PubMed ID: 32986109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: a propensity score-weighted, retrospective, cohort study.
    Mohamad O; Tabuchi T; Nitta Y; Nomoto A; Sato A; Kasuya G; Makishima H; Choy H; Yamada S; Morishima T; Tsuji H; Miyashiro I; Kamada T
    Lancet Oncol; 2019 May; 20(5):674-685. PubMed ID: 30885458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variations in Age-Adjusted Prostate Cancer Incidence Rates by Race and Ethnicity After Changes in Prostate-Specific Antigen Screening Recommendation.
    Lai SM; Keighley J; Garimella S; Enko M; Parker WP
    JAMA Netw Open; 2022 Nov; 5(11):e2240657. PubMed ID: 36342715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.
    Dess RT; Hartman HE; Mahal BA; Soni PD; Jackson WC; Cooperberg MR; Amling CL; Aronson WJ; Kane CJ; Terris MK; Zumsteg ZS; Butler S; Osborne JR; Morgan TM; Mehra R; Salami SS; Kishan AU; Wang C; Schaeffer EM; Roach M; Pisansky TM; Shipley WU; Freedland SJ; Sandler HM; Halabi S; Feng FY; Dignam JJ; Nguyen PL; Schipper MJ; Spratt DE
    JAMA Oncol; 2019 Jul; 5(7):975-983. PubMed ID: 31120534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between African American Race and Clinical Outcomes in Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
    Deka R; Courtney PT; Parsons JK; Nelson TJ; Nalawade V; Luterstein E; Cherry DR; Simpson DR; Mundt AJ; Murphy JD; D'Amico AV; Kane CJ; Martinez ME; Rose BS
    JAMA; 2020 Nov; 324(17):1747-1754. PubMed ID: 33141207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Prostate-Specific Antigen Screening and Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White US Veterans.
    Sherer MV; Qiao EM; Kotha NV; Qian AS; Rose BS
    JAMA Oncol; 2022 Oct; 8(10):1471-1476. PubMed ID: 35925581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
    Moschini M; Zaffuto E; Karakiewicz PI; Andrea DD; Foerster B; Abufaraj M; Soria F; Mattei A; Montorsi F; Briganti A; Shariat SF
    Eur Urol; 2019 Feb; 75(2):319-328. PubMed ID: 30293908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Radiotherapy for Rectal Cancer and Second Gynecological Malignant Neoplasms.
    Guan X; Wei R; Yang R; Lu Z; Liu E; Zhao Z; Chen H; Yang M; Liu Z; Jiang Z; Wang X
    JAMA Netw Open; 2021 Jan; 4(1):e2031661. PubMed ID: 33416884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US.
    Cooperberg MR; Meeks W; Fang R; Gaylis FD; Catalona WJ; Makarov DV
    JAMA Netw Open; 2023 Mar; 6(3):e231439. PubMed ID: 36862409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of Cancer-Associated Venous Thromboembolism in Patients With Solid and Hematologic Neoplasms in the Veterans Affairs Health Care System.
    Martens KL; Li A; La J; May SB; Swinnerton KN; Tosi H; Elbers DC; Do NV; Brophy MT; Gaziano JM; Lotfollahzadeh S; Chitalia V; Ravid K; Fillmore NR
    JAMA Netw Open; 2023 Jun; 6(6):e2317945. PubMed ID: 37306999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disparities in Survival and Comorbidity Burden Between Asian and Native Hawaiian and Other Pacific Islander Patients With Cancer.
    Taparra K; Qu V; Pollom E
    JAMA Netw Open; 2022 Aug; 5(8):e2226327. PubMed ID: 35960520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
    Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
    JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study.
    Nam RK; Cheung P; Herschorn S; Saskin R; Su J; Klotz LH; Chang M; Kulkarni GS; Lee Y; Kodama RT; Narod SA
    Lancet Oncol; 2014 Feb; 15(2):223-31. PubMed ID: 24440474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
    Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
    JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
    Hoffman KE; Penson DF; Zhao Z; Huang LC; Conwill R; Laviana AA; Joyce DD; Luckenbaugh AN; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Koyama T; Barocas DA
    JAMA; 2020 Jan; 323(2):149-163. PubMed ID: 31935027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.